Catalyst Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:CPRX) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 772.01 M851.41 M908.87 M971.91 M1.05 B1.1 B Total liabilities 111.07 M123.78 M114.59 M115.89 M131.36 M149.71 M Total equity 660.94 M727.63 M794.28 M856.03 M920.25 M954.27 M Total liabilities & shareholders' equities 772.01 M851.41 M908.87 M971.91 M1.05 B1.1 B Total debt —————— Net debt ——————

Notizie

Oppenheimer conferma il rating su Catalyst Pharmaceutical dopo i ricavi

Oppenheimer reiterates Catalyst Pharmaceutical stock rating on revenue beat

Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y

Risultati Catalyst Pharmaceuticals in arrivo tra dubbi sulla crescita

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Stock Market Today: Dow Gains As Disney Dives, Pharma Play Eyes Entry, Oracle Pops On This (Live Coverage)

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Jim Cramer: Crane Is A 'Good' Company, Recommends Holding This Tech Stock - Baker Hughes (NASDAQ:BKR), Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript